Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 4 SPEC.ISS., 2004, Pages 641-651

  Ross, Douglas D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; ATP binding cassette; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; COMPLEMENTARY RNA; CYCLOSPORIN; CYCLOSPORIN A; CYTARABINE; CYTOCHROME P450 3A4; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LANIQUIDAR; LUNG RESISTANCE PROTEIN; LY 3335979; MESSENGER RNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; ONT 093; PACLITAXEL; QUININE; TARIQUIDAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VORINOSTAT; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CELL; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TRANSPORT; HUMAN; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT FAILURE; UPREGULATION; VEIN OCCLUSION;

EID: 5744228959     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.014     Document Type: Review

References (80)

1. J.R. Murren V.T. DeVita Another look at multidrug resistance Principles and Practice of Oncology Updates 9 1995 1-12
2. R. Krishna L.D. Mayer Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs European Journal of Pharmaceutical Sciences 11 2000 265-283
3. M.M. Gottesman T. Fojo S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nature Reviews Cancer 2 2002 48-58
4. R.J. Mayer R.B. Davis C.A. Schiffer et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B The New England Journal of Medicine 331 1994 896-903
5. F.R. Appelbaum K.J. Kopecky Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group Cancer 80 1997 2199-2204
6. T. De Witte P. Muus B. De Pauw C. Haanen Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia Cancer 66 1990 831-837
7. T. De Witte S. Suciu M. Peetermans et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG) Leukemia 9 1995 1805-1811
8. D.D. Ross Novel mechanisms of drug resistance in leukemia Leukemia 14 2000 467-473
9. J.E. Karp MDR modulation in acute myelogenous leukemia: is it dead? Leukemia 15 2001 666-667
10. R.S. Weinstein J.R. Kuszak L.F. Kluskens J.S. Coon P-glycoproteins in pathology: the multidrug resistance gene family in humans Human Pathology 21 1990 34-48
11. G.D. Leonard O. Polgar S.E. Bates ABC transporters and inhibitors: new targets, new agents Current Opinion in Investigational Drugs 3 2002 1652-1659
12. E.K. Baker A. El Osta The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer Experimental Cell Research 290 2003 177-194
13. K.W. Scotto Transcriptional regulation of ABC drug transporters Oncogene 22 2003 7496-7511
14. M. Nakayama M. Wada T. Harada et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias Blood 92 1998 4296-4307
15. L.A. Doyle D.D. Ross Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 2003 7340-7358
16. R. Allikmets B. Gerrard A. Hutchinson M. Dean Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database Human Molecular Genetics 5 1996 1649-1655
17. L.A. Doyle W. Yang L.V. Abruzzo et al. A multidrug resistance transporter from human MCF-7 breast cancer cells Proceedings of the National Academy of Sciences of the United States of America 95 1998 15665-15670
18. K. Miyake L. Mickley T. Litman et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes Cancer Research 59 1999 8-13
19. D.D. Ross W. Yang L.V. Abruzzo et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines Journal of the National Cancer Institute 91 1999 429-433
20. M.H. Mossink A. van Zon R.J. Scheper et al. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 22 2003 7458-7467
21. S. Zhou J.D. Schuetz K.D. Bunting et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype Nature Medicine 7 2001 1028-1034
22. D. Bonnet J.E. Dick Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nature Medicine 3 1997 730-737
23. T. Reya S.J. Morrison M.F. Clarke I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105-111
24. C.P. Leith K.J. Kopecky I.M. Chen et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study Blood 94 1999 1086-1099
25. A.F. List C. Spier J. Greer et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia Journal of Clinical Oncology 11 1993 1652-1660
26. A. Samdani U. Vijapurkar M.A. Grimm et al. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML) Leukemia Research 20 1996 175-180
27. C.P. Leith K.J. Kopecky J. Godwin et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood 89 1997 3323-3329
28. M. Pallis Y.M. Zhu N.H. Russell Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression Leukemia 11 1997 945-949
29. M.M. van den Heuvel-Eibrink M.B. van der P.A. te Boekhorst et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia British Journal of Haematology 99 1997 76-83
30. C. Wuchter K. Leonid V. Ruppert et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia Haematologica 85 2000 711-721
31. S.M. Hart K. Ganeshaguru A.V. Hoffbrand et al. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia Leukemia 8 1994 2163-2168
32. E. Schneider K.H. Cowan H. Bader et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia Blood 85 1995 186-193
33. D.C. Zhou R. Zittoun J.P. Marie Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia Leukemia 9 1995 1661-1666
34. M. Filipits R.W. Suchomel S. Zochbauer et al. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome Clinical Cancer Research 3 1997 1419-1425
35. M. Filipits T. Stranzl G. Pohl et al. MRP expression in acute myeloid leukemia. An update Advances in Experimental Medicine and Biology 457 1999 141-150
36. A.F. List C.S. Spier T.M. Grogan et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia Blood 87 1996 2464-2469
37. M. Filipits G. Pohl T. Stranzl et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia Blood 91 1998 1508-1513
38. D. Damiani M. Michieli A. Ermacora et al. P-glycoprotein (PGP) and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias Haematologica 83 1998 290-297
39. D.D. Ross J.E. Karp T.T. Chen L.A. Doyle Expression of breast cancer resistance protein in blast cells from patients with acute leukemia Blood 96 2000 365-368
40. D. Steinbach W. Sell A. Voigt et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia Leukemia 16 2002 1443-1447
41. M.M. van den Heuvel-Eibrink E.A. Wiemer A. Prins et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) Leukemia 16 2002 833-839
42. B.L. Abbott A.M. Colapietro Y. Barnes et al. Low levels of ABCG2 expression in adult AML blast samples Blood 100 2002 4594-4601
43. D.M. van der Kolk E. Vellenga G.L. Scheffer et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia Blood 99 2002 3763-3770
44. D.R. Ferry H. Traunecker D.J. Kerr Clinical trials of P-glycoprotein reversal in solid tumours European Journal of Cancer 32A 1996 1070-1081
45. R. Advani H.I. Saba M.S. Tallman et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar) Blood 93 1999 787-795
46. G.V. Dahl N.J. Lacayo N. Brophy et al. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia Journal of Clinical Oncology 18 2000 1867-1875
47. G. Visani S. Buonamici M. Malagola et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study Leukemia 15 2001 1696-1700
48. R. Dorr C. Karanes C. Spier et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia Journal of Clinical Oncology 19 2001 1589-1599
49. J.E. Kolitz S.L. George D.D. Hurd et al. Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with acute myeloid leukemia (AML) <60 years old: preliminary results of CALGB 9621 Blood 94 1999 384a. (abstr.)
50. E.J. Lee S.L. George M. Caligiuri et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420 Journal of Clinical Oncology 17 1999 2831-2839
51. J.E. Kolitz S.L. George J.E. Dodge et al. Dose escalation studies of Ara-C (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) <60 years: final induction results of CALGB 9621 Blood 98 2001 461a. (abstr.)
52. S.S. Farag S.L. George E.J. Lee et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420 Clinical Cancer Research 8 2002 2812-2819
53. E. Solary B. Witz D. Caillot et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study Blood 88 1996 1198-1205
54. P. Greenberg R. Advani M. Tallman et al. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) ves MEC: randomized Phase III trial (E2995) Blood 94 1999 383a. (abstr.)
55. J.A. Liu Yin K. Wheatley J.K. Rees A.K. Burnett Comparison of sequential versus standard chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial British Journal of Haematology 113 2001 713-726
56. M.R. Baer S.L. George R.K. Dodge et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood 100 2002 1224-1232
57. A.F. List K.J. Kopecky C.L. Willman et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study Blood 98 2001 3212-3220
58. T.R. Chauncey C. Rankin J.E. Anderson et al. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617 Leukemia Research 24 2000 567-574
59. S. Bates M. Kang B. Meadows et al. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar) Cancer 92 2001 1577-1590
60. L. van Zuylen A. Sparreboom G.A. van der et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel Clinical Cancer Research 6 2000 1365-1371
61. A. Sandler M. Gordon D.P. de Alwis et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy Clinical Cancer Research 10 2004 3265-3272
62. E.S. Guns T. Denyssevych R. Dixon et al. Drug interaction studies between paclitaxel (Taxol) and OC144-093-a new modulator of MDR in cancer chemotherapy European Journal of Drug Metabolism and Pharmacokinetics 27 2002 119-126
63. C.L. Willman Molecular evaluation of acute myeloid leukemias Seminars in Hematology 36 1999 390-400
64. J. Kemnitz M. Freund M. Dominis et al. Detection of cells with multidrug-resistant phenotype in myeloproliferative disorders before therapy Hematolology and Pathology 3 1989 73-78
65. J. Holmes A. Jacobs G. Carter et al. Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia British Journal of Haematology 72 1989 40-44
66. L. Campos D. Guyotat E. Archimbaud et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis Blood 79 1992 473-476
67. S. Zochbauer A. Gsur M. Gotzl et al. MDR1 gene expression in myelodysplastic syndrome and in acute myeloid leukemia evolving from myelodysplastic syndrome Anticancer Research 14 1994 1293-1295
68. P. Lepelley V. Soenen C. Preudhomme et al. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes Leukemia 8 1994 998-1004
69. A.F. List C.M. Spier A. Cline et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype British Journal of Haematology 78 1991 28-34
70. S. Poulain P. Lepelley C. Preudhomme et al. Expression of the multidrug resistance-associated protein in myelodysplastic syndromes British Journal of Haematology 110 2000 591-598
71. P. Lepelley S. Poulain N. Grardel et al. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes Leukemia and Lymphoma 29 1998 547-551
72. E. Wattel E. Solary B. Hecquet et al. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Francais des Myelodysplasies (GFM) and Groupe GOELAMS Advances in Experimental Medicine and Biology 457 1999 35-46
73. A. Tsimberidou E. Estey J. Cortes et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes Cancer 97 2003 1481-1487
74. M.L. Linenberger T. Hong D. Flowers et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood 98 2001 988-994
75. V. Fischer A. Rodriguez-Gascon F. Heitz et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug - Drug interactions and pharmacological activity of the main metabolite Drug Metabolism and Disposition 26 1998 802-811
76. S.F. Bates C. Chen R. Robey et al. Reversal of multidrug resistance: lessons from clinical oncology Novartis Foundation Symposium 243 2002 83-96
77. A.M. Oza Clinical development of P glycoprotein modulators in oncology Novartis Foundation Symposium 243 2002 103-115
78. A.A. Ruefli D. Bernhard K.M. Tainton et al. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells International Journal of Cancer 99 2002 292-298
79. H. Wu W.N. Hait J.M. Yang Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells Cancer Research 63 2003 1515-1519
80. H. Minderman K.L. O'Loughlin L. Pendyala M.R. Baer VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein Clinical Cancer Research 10 2004 1826-1834